substance P

Although most chemicals cannot pass from the blood into the brain, substance P, they discovered, can.

It is a mixture of inflammation and substance P that are responsible for pain.

They do not have "substance p," a neurotransmitter that projects pain.

Substance P is an important element in pain perception.

It's thought that when substance P levels are elevated in the body, they may produce higher levels of pain.

Substance P is the most researched and potent member of the tachykinin family.

Current studies focus on whether controlling Substance P expression may control tooth pain.

Merck also has hopes of using Substance P as a treatment for depression.

Substance P helps nervous system cells send messages to each other about painful stimuli.

Substance P also has effects as a potent vasodilator.

An early study in animal models showed that substance P induced by capsaicin stimulated hair growth.

The sensory function of substance P is thought to be related to the transmission of pain information into the central nervous system.

Not only did substance P work, they found, but it did not even have to be injected directly into the brain.

Several companies are exploring drugs that block the action of Substance P, though experts say studies have yielded inconsistent results.

At least one company, Merck, has a Substance P drug in clinical trials.

Pain relief should occur gradually as the substance P in your body is decreased in the nerve cells.

Substance P is an undecapeptide responsible for transmission of pain from certain sensory neurons to the central nervous system.

This is due to the receptor binding with substance P, a peptide neurotransmitter.

Earlier this month, the company announced that it had abandoned tests of aprepitant, also known as Substance P, for depression.

These cells contain the peptides (small proteins), substance P and somatostatin (among others).

The deduced amino acid sequence of substance P is as follows:

Other substances known to induce itch are substance P, cytokines, and proteases.

It may also reduce pain in patients by inhibiting the release of substance P in the spinal cord, as well.

In the final common pathway, substance P, which activates the Neurokinin-1 receptor, appears to be involved.

Scientists discovered that by blocking the Substance P receptors, they might treat everything from migranes to anxiety.